Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28

This Phase 2a, multicenter, randomized, subject-blind, investigator-blind study was designed to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis. The study enrolled 49 subjects. The primary outcomes were the change from baseline in Psoriasis Area and Severity Index (PASI) at Week 28, the plasma concentration of bimekizumab at baseline, and the plasma concentration of bimekizumab at Week 2. The study was sponsored by UCB Biopharma SRL, started on December 27, 2016, and had a primary completion date of December 11, 2017. Results were posted on January 6, 2021. The abstract does not provide specific numerical results for the PASI change or the plasma concentration values. No safety signals or specific limitations are detailed in the provided abstract text.